Replies to post #156534 on Biotech Values

[mcbio]

GT3 patients will also have the option to be treated with Sofosbuvir/PegRiba until a more viable oral combination is developed.

What is your prediction of what will be the first viable oral combo for GT3? Is it presumably going to include some, or perhaps all, drug components that aren't even in the clinic right now? Presumably a nuke is still going to be the backbone, whether that's sofosbuvir or some follow-on uridine nuke.

[genisi]

GT3 patients will also have the option to be treated with Sofosbuvir/PegRiba until a more viable oral combination is developed.

So, why not try sofo+riba first and those not cured can either wait for a more viable oral combination like sofo+GS-5816 or elect to go with the Sofosbuvir/PegRiba treatment. I think patients, docs and the FDA itself want to get rid of peg-inf and I really don't see anyone trying a non oral interferon containing combo ahead of an oral inf-free one. IMO, if data from all trials show non-inferiority to SoC, then the FDA will approve (perhaps restrict cirrhotic GT3 patients). Even if the FDA will only approve sofo+peg/riba in GT3, I still think we'll see off-label use of the oral combo.